Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORVax12 vaccine for SARS-CoV-2
NCT04627675Phase 1Terminated
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- Viral Vector Vaccines, Peptides, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of CORVax12 in coronavirus disease 2019 (COVID-19). Started Dec 2020; status: terminated.
02
Drugs
CORVax12
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04627675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627675.